延长筛查间隔时代的宫颈癌筛查随访模式
研究利用IBM Watson Health MarketScan数据库纳入2013至2019年间接受宫颈癌初筛的30至64岁美国商业保险女性,评估重复筛查的依从性。共识别5,368,713例患者,联合检测占53.5%、细胞学占45.1%、初筛HPV检测占1.4%。七年内重复筛查累积发生率为81.9%,但重复筛查者中绝大多数早于现行指南推荐间隔。
要点
- 初筛联合检测占53.5%,细胞学占45.1%,初筛HPV检测占1.4%。
- 所有女性七年内重复筛查累积发生率为81.9%。
- 重复筛查者中,初筛细胞学85.7%、初筛联合检测96.6%提前复筛。
核心结论
- 适当的宫颈癌随访筛查变异很大,重复筛查累积发生率为81.9%,重复筛查女性中绝大多数早于现行指南推荐间隔检测。
研究设计与样本
- 使用IBM Watson Health MarketScan数据库识别2013至2019年接受宫颈癌筛查的30至64岁商业保险女性。
- 队列限于初筛前12个月及初筛后至少2个月持续参保者,排除既往子宫切除、需更频繁监测或细胞学、组织学、HPV检测异常史者。
- 初筛包括细胞学、联合检测或初筛HPV检测,采用累积发生率曲线描述筛查间隔,并以原因别风险模型分析依从性相关因素。
主要发现
- 共识别5,368,713例患者,联合检测2,873,070例(53.5%),细胞学2,422,480例(45.1%),初筛HPV检测73,163例(1.4%)。
- 所有女性七年内重复筛查累积发生率为81.9%。
- 重复筛查者中,初筛细胞学85.7%提前复筛,初筛联合检测96.6%提前复筛。
- 初筛细胞学者仅12.2%按适当间隔复筛、2.1%延迟复筛;初筛联合检测者3.2%按适当间隔复筛、0.3%延迟复筛。
关键数值与推荐
- 依从性定义为初筛细胞学后2.5至4年、初筛联合检测后4.5至6年发生重复筛查。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Little is known as to how prolonged screening recommendations for cervical cancer have affected compliance. OBJECTIVE: We examined compliance with repeat cervical cancer screening among U.S. women aged 30-64 who underwent index screening between 2013 and 2019. STUDY DESIGN: The IBM Watson Health MarketScan Database was used to identify commercially-insured women 30-64 years old who underwent cervical cancer screening from 2013 to 2019. The cohort was limited to women with continuous insurance 12 months before and ≥ 2 months after index testing. Patients with prior hysterectomy, more frequent surveillance needs, or a history of abnormal cytology, histology, or HPV test were excluded. Index screening included cytology, co-testing, or primary HPV testing. Cumulative incidence curves described screening intervals. Compliance was considered if repeat screening occurred 2.5-4 years after index cytology and 4.5-6 years after index co-testing. Cause-specific hazard models examined factors associated with compliance. RESULTS: Of 5,368,713 patients identified, co-testing was performed in 2,873,070 (53.5%), cytology in 2,422,480 (45.1%), and primary HPV testing in 73,163 (1.4%). The cumulative incidence of repeat screening among all women by seven years was 81.9%. Of those who underwent repeat screening, 85.7% with index cytology and 96.6% with index co-testing were rescreened early. Only, 12.2% with index cytology had appropriate rescreening and 2.1% had delayed rescreening. Among the index co-testing group, 3.2% had appropriate rescreening and 0.3% had delayed rescreening. CONCLUSION: Appropriate cervical cancer follow-up screening is highly variable. The cumulative incidence rate of repeat screening was 81.9% and among women rescreened, the vast majority are tested earlier than recommended by current guidelines.
引用
- Kulkarni A, Chen L, Gockley A, et al. Patterns of cervical cancer screening follow-up in the era of prolonged screening intervals. Gynecol Oncol. 2023. PMID: 37327539. doi:10.1016/j.ygyno.2023.06.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。